Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73176 | 0.72 | HTR2A (0.52) | HTR2ACA1CA2HDAC3HDAC4 | |
| SCHEMBL1509217 | 0.72 | HTR2A (0.47) | HTR2ACA1CA2HDAC3HDAC4 | |
| SCHEMBL8917026 | 0.72 | CA1 (0.49) | HTR2ACA1CA2HDAC3HDAC4 | |
| SCHEMBL88302 | 0.71 | HTR2A (0.45) | HTR2AHDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21896104 | 0.71 | HTR2A (0.45) | HTR2ACA1CA2HDAC3HDAC4 | |
| SCHEMBL1567087 | 0.71 | HTR2A (0.45) | HTR2ACA1CA2HDAC3HDAC4 | |
| SCHEMBL29579635 | 0.71 | HTR2A (0.45) | HTR2AHDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL7052087 | 0.71 | KMT2A (0.46) | HTR2ACA1CA2HDAC3HDAC4 | |
| SCHEMBL2121843 | 0.69 | HTR2A (0.48) | HTR2ACA1CA2HDAC3HDAC4 | |
| SCHEMBL21895871 | 0.69 | MTNR1A (0.49) | HTR2AHDAC3HDAC4HDAC7HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396492-B2 | Direct oxidative amination of hydrocarbons | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200377448-A1 | DIRECT OXIDATIVE AMINATION OF HYDROCARBONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-03 | — | — | US | disclosed |
| CN-111757866-A | Direct oxidative amination of hydrocarbons | 斯克利普斯研究所 | 2020-10-09 | — | — | CN | disclosed |
| EP-3717454-A1 | DIRECT OXIDATIVE AMINATION OF HYDROCARBONS | The Scripps Research Institute (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2681187-B1 | PROCESS FOR REDUCTION OF ALPHA-ACYLOXY SULFIDE DERIVATIVES | SCINOPHARM TAIWAN LTD (TW) | 2018-04-11 | — | — | EP | disclosed |
| US-8722921-B2 | Process for reduction of alpha-acyloxy sulfide derivatives | SCINOPHARM SINGAPORE PTE, LTD. (SG) | 2014-05-13 | — | — | US | disclosed |
| EP-2681187-A1 | PROCESS FOR REDUCTION OF -ACYLOXY SULFIDE DERIVATIVES | Scinopharm Taiwan Ltd. (TW) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012118441-A1 | PROCESS FOR REDUCTION OF α-ACYLOXY SULFIDE DERIVATIVES | SCINOPHARM SINGAPORE PTE, LTD. (SG) | 2012-09-07 | — | — | WO | disclosed |
| US-20120220784-A1 | PROCESS FOR REDUCTION OF ALPHA-ACYLOXY SULFIDE DERIVATIVES | SCINOPHARM SINGAPORE PTE, LTD. (SG) | 2012-08-30 | — | — | US | disclosed |
| US-8158796-B2 | Process for the preparation of Rho-kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2291077-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | Inspire Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100022775-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2009154940-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-0763523-B1 | NAPHTHALENE DERIVATIVE | TEIJIN LTD (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5945450-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1999-08-31 | — | — | US | disclosed |
| US-5633364-A | N4 -substituted 2'-deoxycytidine compounds, oligonucleotides including N4 -labeled 2'-deoxycytidines, and a process for making oligonucleotides with N-modified 2'-deoxycytidines | AMOCO CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| EP-0763523-A1 | NAPHTHALENE DERIVATIVE | TEIJIN LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-5405950-A | N4 -substituted cytidines and process for incorporation into an oligonucleotides | AMOCO CORPORATION (US) | 1995-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022775-A1 | PROCESS FOR THE PREPARATION OF RHO-KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | HTR2A 4780/4885CA1 4028/4885CA2 1786/4885 |
| US-20120220784-A1 | PROCESS FOR REDUCTION OF ALPHA-ACYLOXY SULFIDE DERIVATIVES | SULT1A1, SQOR, SULT2A1 | HTR2A 4149/4885CA1 2242/4885CA2 2794/4885 |
| US-11396492-B2 | Direct oxidative amination of hydrocarbons | GPX4, AOC2, NOX1 | HTR2A 2069/4885CA1 1725/4885CA2 3243/4885 |
| US-20200377448-A1 | DIRECT OXIDATIVE AMINATION OF HYDROCARBONS | GPX4, AOC2, NOX1 | HTR2A 2069/4885CA1 1725/4885CA2 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.